

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

NCT05291845

Status	RECRUITING
Phase	Phase 2
Sponsor	Zagazig University
Enrollment	162 participants

Key Eligibility Criteria

Inclusion (1)

- patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study

Exclusion (1)

- Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine

Locations (1 total)

Reham Essam, Zagazig, Al Sharqia, Egypt